Careteq (ASX:CTQ) Common Stock: A$25.49 Mil (As of Dec. 2025)


What is Careteq Common Stock?

Careteq ASX:CTQ Common Stock is A$25.49 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Careteq's quarterly common stock stayed the same from Dec. 2024 (A$25.49 Mil) to Jun. 2025 (A$25.49 Mil) and stayed the same from Jun. 2025 (A$25.49 Mil) to Dec. 2025 (A$25.49 Mil).

Careteq's annual common stock increased from Jun. 2023 (A$22.96 Mil) to Jun. 2024 (A$25.49 Mil) but then stayed the same from Jun. 2024 (A$25.49 Mil) to Jun. 2025 (A$25.49 Mil).

Careteq Common Stock Historical Data

* Premium members only.

The historical data trend for Careteq's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Careteq Common Stock Chart

Careteq Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
21.28 22.96 22.96 25.49 25.49

Careteq Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only 25.46 25.49 25.49 25.49 25.49

Careteq Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$25.49 Mil mean?
Careteq (ASX:CTQ) has a Common Stock of A$25.49 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Careteq and its competitors.
Is Careteq's Common Stock too high?
Careteq's current Common Stock is A$25.49 Mil.
How does Careteq's Common Stock compare to VEEV and BTSG?
Careteq's Common Stock of A$25.49 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Healthcare Providers & Services company?
A good Common Stock depends on the Healthcare Providers & Services industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Careteq and its competitors. Careteq's current Common Stock is A$25.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careteq stock overvalued right now?
Based on GuruFocus' analysis, Careteq (ASX:CTQ) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% above its estimated fair value. The current Common Stock is A$25.49 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Careteq (ASX:CTQ), the current Common Stock is A$25.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Careteq Business Description

Address 99 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
Careteq Ltd provides Residential Medication Management Review and Home Medicines Review services as part of the Medication Management Programs, generating revenue from medication review, education, and support services. The company focuses on medication management and home care solutions to provide continuity of care and improve clinical outcomes for patients through Home Medication Reviews. Medication-related harm includes adverse drug reactions, medication errors, and complications that jeopardise patient safety and increase healthcare costs. The company operates in Australia.